Přihlásit se Zaregistrujte se zdarma

1letý cíl společnosti Adaptimmune Therapeutics Plc

Jaká je hodnota metriky 1letý cíl společnosti Adaptimmune Therapeutics Plc?

Hodnota metriky 1letý cíl společnosti Adaptimmune Therapeutics Plc je $11 +949.07%

Jaká je definice metriky 1letý cíl?

1-letý cíl (1-year target) je analytiky předpokládaná cena akcie za rok od dnešního dne.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1letý cíl společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Adaptimmune Therapeutics Plc

Čemu se věnuje společnost Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Firmy s metrikou 1letý cíl podobnou společnosti Adaptimmune Therapeutics Plc